BioMarin Hid 'Revolutionary' Drug's Troubles, Investor Says
California-based BioMarin Pharmaceutical Inc. and two of its executives face an investor suit accusing them of failing to disclose troubles facing its "revolutionary" Hemophilia A gene therapy Valrox during its testing...To view the full article, register now.
Already a subscriber? Click here to view full article